Mark Genovese
Corporate Officer/Principal bei ELI LILLY AND COMPANY
Profil
Mark Genovese is currently the Senior Vice President-Immunology Development at Eli Lilly & Co. He previously worked as the Director at Kyverna Therapeutics, Inc. and as the Clinical Chief-Immunology & Rheumatology at Stanford University.
From 2020 to 2023, he served as the Senior Vice President-Inflammation Development at Gilead Sciences, Inc. Dr. Genovese completed his undergraduate degree at the University of Notre Dame and obtained his doctorate from The Johns Hopkins University School of Medicine.
Aktive Positionen von Mark Genovese
| Unternehmen | Position | Beginn |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 16.10.2023 |
Ehemalige bekannte Positionen von Mark Genovese
| Unternehmen | Position | Ende |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.09.2023 |
| KYVERNA THERAPEUTICS, INC. | Director/Board Member | - |
| Stanford University | Corporate Officer/Principal | - |
Ausbildung von Mark Genovese
| University of Notre Dame | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| KYVERNA THERAPEUTICS, INC. | Health Technology |
